tetano
Editor, Senior Moderator
Vaccine. 2019 Mar 23. pii: S0264-410X(19)30316-0. doi: 10.1016/j.vaccine.2019.02.078. [Epub ahead of print]
[h=1]Vaccine-mediated protection of pigs against infection with pandemic H1N1 2009 swine influenza A virus requires a close antigenic match between the vaccine antigen and challenge virus.[/h] Everett HE[SUP]1[/SUP], Aramouni M[SUP]2[/SUP], Coward V[SUP]3[/SUP], Ramsay A[SUP]3[/SUP], Kelly M[SUP]3[/SUP], Morgan S[SUP]4[/SUP], Tchilian E[SUP]4[/SUP], Canini L[SUP]5[/SUP], Woolhouse MEJ[SUP]5[/SUP], Gilbert S[SUP]2[/SUP], Charleston B[SUP]4[/SUP], Brown IH[SUP]3[/SUP], Brookes SM[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Swine influenza A virus (SwIV) infection has considerable economic and animal welfare consequences and, because of the zoonotic potential, can also have public health implications. The 2009 pandemic H1N1 'swine-origin' infection is now endemic in both pigs and humans. In Europe, avian-like H1[SUB]av[/SUB]N1, human-like H1[SUB]hu[/SUB]N2, human-like swine H3N2 and, since 2009, pandemic H1N1 (pH1N1) lineage viruses and reassortants, constitute the dominant subtypes. In this study, we used a swine pH1N1 challenge virus to investigate the efficacy of whole inactivated virus vaccines homologous or heterologous to the challenge virus as well as a commercial vaccine. We found that vaccine-mediated protection was most effective when vaccine antigen and challenge virus were homologous and correlated with the specific production of neutralising antibodies and a cellular response to the challenge virus. We conclude that a conventional whole inactivated SwIV vaccine must be antigenically matched to the challenge strain to be an effective control measure.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] H1N1; Immune response; Pandemic 2009 influenza A virus; Swine influenza A virus; Whole inactivated virus vaccine
PMID: 30914224 DOI: 10.1016/j.vaccine.2019.02.078
[h=1]Vaccine-mediated protection of pigs against infection with pandemic H1N1 2009 swine influenza A virus requires a close antigenic match between the vaccine antigen and challenge virus.[/h] Everett HE[SUP]1[/SUP], Aramouni M[SUP]2[/SUP], Coward V[SUP]3[/SUP], Ramsay A[SUP]3[/SUP], Kelly M[SUP]3[/SUP], Morgan S[SUP]4[/SUP], Tchilian E[SUP]4[/SUP], Canini L[SUP]5[/SUP], Woolhouse MEJ[SUP]5[/SUP], Gilbert S[SUP]2[/SUP], Charleston B[SUP]4[/SUP], Brown IH[SUP]3[/SUP], Brookes SM[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Swine influenza A virus (SwIV) infection has considerable economic and animal welfare consequences and, because of the zoonotic potential, can also have public health implications. The 2009 pandemic H1N1 'swine-origin' infection is now endemic in both pigs and humans. In Europe, avian-like H1[SUB]av[/SUB]N1, human-like H1[SUB]hu[/SUB]N2, human-like swine H3N2 and, since 2009, pandemic H1N1 (pH1N1) lineage viruses and reassortants, constitute the dominant subtypes. In this study, we used a swine pH1N1 challenge virus to investigate the efficacy of whole inactivated virus vaccines homologous or heterologous to the challenge virus as well as a commercial vaccine. We found that vaccine-mediated protection was most effective when vaccine antigen and challenge virus were homologous and correlated with the specific production of neutralising antibodies and a cellular response to the challenge virus. We conclude that a conventional whole inactivated SwIV vaccine must be antigenically matched to the challenge strain to be an effective control measure.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] H1N1; Immune response; Pandemic 2009 influenza A virus; Swine influenza A virus; Whole inactivated virus vaccine
PMID: 30914224 DOI: 10.1016/j.vaccine.2019.02.078